진매트릭스

109820KOSDAQ자연과학 및 공학 연구개발업

50.3 / 100

Reference Date: 2026-06-10

Financial Score17.0 / 40

News Sentiment21.3 / 25

Momentum2.0 / 20

Disclosure10.0 / 15

AI Analysis: PBR is significantly undervalued vs. peers but the high debt ratio poses financial risk. Plunged 16.5% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

JinMatrix is a biotechnology company established in 2000, specializing in the development of pharmaceuticals and diagnostic kits using proprietary technologies such as C-Tag and Encleap. Its flagship product, NeoPlex, enables the simultaneous detection of multiple pathogens, including sexually transmitted infections, tuberculosis, and HPV, and the company is expanding into global molecular diagnostics markets, particularly in Europe.

Number of Employees

69people

Average Salary

47.3M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 62.704.0Point

PBR

1.87Industry Average 3.245.5Point

Lower than industry avg (good)

ROE

-10.00Industry Average -32.093.5Point

Well below industry avg

Debt Ratio

29.33Industry Average 7.310.0Point

4.0x industry avg (risky)

Trend 2023~20254.0 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲4.2% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲47.1% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -10.5% (declining, 3yr)

Detailed News Sentiment

1 totalPositive 1Neutral 0Negative 0Average Sentiment Score 85

Positive
진매트릭스, 바이러스 인공 생성기술 ‘AIVIS’ 특허 출원
진매트릭스의 AI 기반 바이러스 합성 원천기술 특허 출원으로 백신 개발 경쟁력이 강화되어 긍정적인 시장 반응 예상.

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 1,599Won52-week high 3,24552-week low 1,599

1-month return0.0Point

1m -16.50% (strong drop)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral분기보고서 (2026.03)2026-05-15